Sentiment Trading

NeuroPace Inc. has achieved safety milestones with its RNS System, but a recent clinical trial fell short on efficacy, leaving the company at a crossroads with investors and stakeholders in a state of cautious optimism.

NeuroPace Inc. has reported a 24% increase in revenue for Q1 2025, driven by its expanding presence in the epilepsy treatment market.